Abstract
Objective/background: Data generated from retrospective studies on primary mediastinal Bcell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma. Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints. Results: In our cohort, 27 (66%) cases were treated with R-CHOP and 14 (34%) cases were treated with DA-EPOCH-R. The overall median follow-up time was 34 months. Among the patients treated with R-CHOP, 23 out of 27 (92.6%) patients achieved CR; similarly, 10 out of 14 patients (85.7%) in the DA-EPOCH-R group achieved CR after initial treatment. There were no differences in OS between patients treated with R-CHOP versus DA-EPOCH-R.Conclusion: The findings of this study indicate that combined chemotherapy and immunotherapy results in excellent long-term outcome of patients with PMBCL. At our center, we prefer RCHOP to DA-EPOCH-R for low-risk patients with nonbulky disease.
Recommended Citation
Elhagracy, Rehab; Hamadah, Abdulaziz; Tawab, Rasha abd el; Pinto, Karen; Hussain, Amany; Osmani, Mohammad; and Alshemmari, Salem
(2022)
"Primary mediastinal large B-cell lymphoma : Impact of chemotherapy choice,"
Hematology/Oncology and Stem Cell Therapy: Vol. 15
:
Iss.
4
, Article 5.
Available at: https://doi.org/10.1016/j.hemonc.2021.05.002
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
